
Paxman Q4'2024 - Outlook is still excellent and CIPN becoming the real deal

Redeye saw a report with sales that were lower than our expectations. The underlying metrics are generally positive, and 2025e is a year to prepare for the expected sales boost in the US in 2026e. We have adjusted our sales trajectory but expect to include CIPN in an upcoming update. We increase our fair value range and Base case. Following this report, we also change the lead analyst for Paxman.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Paxman Q4'2024 - Outlook is still excellent and CIPN becoming the real deal](#)